An evaluation of the efficacy of vasoactive intestinal polypeptide antagonists in vivo in the anaesthetized dog

F. Markos; B. A. Hennessy; M. Fitzpatrick; J. O'Sullivan; H. M. Snow

doi:10.1159/000065535

An evaluation of the efficacy of vasoactive intestinal polypeptide antagonists in vivo in the anaesthetized dog

F. Markos
, B. A. Hennessy
, M. Fitzpatrick
, J. O'Sullivan
, H. M. Snow

School of Medicine

Research output: Contribution to journal › Article › peer-review

Abstract

The effectiveness of competitive peptide vasoactive intestinal polypeptide (VIP) receptor antagonists was evaluated on heart rate in the anaesthetized dog. Two specific antagonists, VIP (6-28) and [D-p-Cl-Phe⁶, Leu¹⁷]-VIP, and a nonspecific antagonist, pituitary adenylate cyclase activating peptide fragment (6-27) (PACAP), were studied. VIP (6-28) and [D-p-Cl-Phe⁶, Leu¹⁷]-VIP (100 μg i.c.) increased the heart rate, whereas PACAP (100 μg i.c.) reduced the baseline heart rate. All three shifted the VIP dose-response curve to the right by two- to threefold for 30 min. In conclusion, PACAP, VIP (6-28), and [D-p-Cl-Phe⁶, Leu¹⁷]-VIP have a direct effect on the heart rate, are equally effective, and the effects last approximately 30 min in vivo. Copyright

Original language	English
Pages (from-to)	206-210
Number of pages	5
Journal	Pharmacology
Volume	66
Issue number	4
DOIs	https://doi.org/10.1159/000065535
Publication status	Published - 2002

Keywords

[D-p-Cl-Phe, Leu]-VIP
Heart, dog
PACAP (6-27)
VIP (6-28)
VIP antagonists

Access to Document

10.1159/000065535

Cite this

@article{81a5bbc7687c4598bfae947af88a0e35,

title = "An evaluation of the efficacy of vasoactive intestinal polypeptide antagonists in vivo in the anaesthetized dog",

abstract = "The effectiveness of competitive peptide vasoactive intestinal polypeptide (VIP) receptor antagonists was evaluated on heart rate in the anaesthetized dog. Two specific antagonists, VIP (6-28) and [D-p-Cl-Phe6, Leu17]-VIP, and a nonspecific antagonist, pituitary adenylate cyclase activating peptide fragment (6-27) (PACAP), were studied. VIP (6-28) and [D-p-Cl-Phe6, Leu17]-VIP (100 μg i.c.) increased the heart rate, whereas PACAP (100 μg i.c.) reduced the baseline heart rate. All three shifted the VIP dose-response curve to the right by two- to threefold for 30 min. In conclusion, PACAP, VIP (6-28), and [D-p-Cl-Phe6, Leu17]-VIP have a direct effect on the heart rate, are equally effective, and the effects last approximately 30 min in vivo. Copyright",

keywords = "[D-p-Cl-Phe, Leu]-VIP, Heart, dog, PACAP (6-27), VIP (6-28), VIP antagonists",

author = "F. Markos and Hennessy, \{B. A.\} and M. Fitzpatrick and J. O'Sullivan and Snow, \{H. M.\}",

year = "2002",

doi = "10.1159/000065535",

language = "English",

volume = "66",

pages = "206--210",

journal = "Pharmacology",

issn = "0031-7012",

publisher = "S. Karger AG",

number = "4",

}

TY - JOUR

T1 - An evaluation of the efficacy of vasoactive intestinal polypeptide antagonists in vivo in the anaesthetized dog

AU - Markos, F.

AU - Hennessy, B. A.

AU - Fitzpatrick, M.

AU - O'Sullivan, J.

AU - Snow, H. M.

PY - 2002

Y1 - 2002

N2 - The effectiveness of competitive peptide vasoactive intestinal polypeptide (VIP) receptor antagonists was evaluated on heart rate in the anaesthetized dog. Two specific antagonists, VIP (6-28) and [D-p-Cl-Phe6, Leu17]-VIP, and a nonspecific antagonist, pituitary adenylate cyclase activating peptide fragment (6-27) (PACAP), were studied. VIP (6-28) and [D-p-Cl-Phe6, Leu17]-VIP (100 μg i.c.) increased the heart rate, whereas PACAP (100 μg i.c.) reduced the baseline heart rate. All three shifted the VIP dose-response curve to the right by two- to threefold for 30 min. In conclusion, PACAP, VIP (6-28), and [D-p-Cl-Phe6, Leu17]-VIP have a direct effect on the heart rate, are equally effective, and the effects last approximately 30 min in vivo. Copyright

AB - The effectiveness of competitive peptide vasoactive intestinal polypeptide (VIP) receptor antagonists was evaluated on heart rate in the anaesthetized dog. Two specific antagonists, VIP (6-28) and [D-p-Cl-Phe6, Leu17]-VIP, and a nonspecific antagonist, pituitary adenylate cyclase activating peptide fragment (6-27) (PACAP), were studied. VIP (6-28) and [D-p-Cl-Phe6, Leu17]-VIP (100 μg i.c.) increased the heart rate, whereas PACAP (100 μg i.c.) reduced the baseline heart rate. All three shifted the VIP dose-response curve to the right by two- to threefold for 30 min. In conclusion, PACAP, VIP (6-28), and [D-p-Cl-Phe6, Leu17]-VIP have a direct effect on the heart rate, are equally effective, and the effects last approximately 30 min in vivo. Copyright

KW - [D-p-Cl-Phe, Leu]-VIP

KW - Heart, dog

KW - PACAP (6-27)

KW - VIP (6-28)

KW - VIP antagonists

UR - https://www.scopus.com/pages/publications/0036970155

U2 - 10.1159/000065535

DO - 10.1159/000065535

M3 - Article

C2 - 12393943

AN - SCOPUS:0036970155

SN - 0031-7012

VL - 66

SP - 206

EP - 210

JO - Pharmacology

JF - Pharmacology

IS - 4

ER -

An evaluation of the efficacy of vasoactive intestinal polypeptide antagonists in vivo in the anaesthetized dog

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this